, o changes were: not anticipated (72. 9%, 77.8% in 2016, 70.9% in 2015) , expected by 12/18=8.5%, by 12/19=11.9% or by 12/20=3.4% • Plan requirement for the submission of AMCP dossiers and budget impact models for committee reviews are shown in Figure 4 Figure 4: Requirements for Dossiers and Budget Impact Models (BIMs)
CONCLUSIONS
• The managed care P&T Committee decision-making process is undergoing a series of changes • Medical and Pharmacy Directors, who commonly serve as P&T Committee members, have distinct opinions as to how to alter the process to adapt to these influences • Oncology continues to be a constantly growing concern for health plans • Biosimilars offer potential for budgetary relief, however the timing is uncertain o Although most were happy with their medical-benefit, among the 89.2% desiring a change, the most requested changes were: -Moving all drugs to the pharmacy-benefit where they can be managed (24.2%) -Having access to better data from electronic medical records, data integration, better reimbursement coding (15.2%) -A better prior authorization process (12.1%) -More disease management (9.1%) o Top concerns today and in the future included Cancer, Diabetes, and Cardiovascular diseases (Table 1) (20), Genetic Therapy (6), Biologics (4), Rare Diseases (4) o 2nd highest: Oncology (10), Rare Diseases (5), Immunotherapy (4) o 3rd highest: Oncology (7), Heart Disease (4), Immunotherapy (4), Rare Diseases (4)
RESULTS CONTINUED
Mental Health Care Self-Administered Agents (3) Oncology (26), Diabetes (6), Hepatitis-C (5), Heart Disease (3) 2 nd Diabetes (9), Heart Disease (7), Oncology (7), COPD (4) Oncology (9), Heart Disease (7), Rheumatoid Arthritis (7), Hepatitis-C (5) o Plan coverage and benefit design: -Geographical coverage -Clinical-administered products (office administered products) -Coverage of mental health drugs -Changes desired in benefit design and coverage -Open ended questions on top concerns from medical and budgetary points of view and classes expected to experience the most growth o Plan requirements for and use of AMCP dossiers and budget impact models o Plan reviews for biosimilar agents that have entered or are likely to enter the market in the US • Survey responses were compared with prior surveys • Survey invitations were received and reviewed by 247 managed care decision makers
RESULTS
• A total of 77 respondents (31.2% response rate) completed the survey, some questions were not answered by all respondents • Many respondents reported multiple degrees (Figure 1) , and the most common degree was MD (57%) o 40.5% worked for health plans, 11.4% PBMs, 8.9% Integrated Delivery Networks (IDNs), 3.8% for Preferred Prescriber Organizations (PPOs) / Independent Provider Associations (IPAs), 1.3% for the Government, the remainder consultants o 39.2% of plans were national=39.2%, 27.5% were regional and 33.3% were local o The most commonly reported respondent titles were: Chief / Senior Officer (43%), Payor specific (19%), Regional (8.9%), or therapeutic area specific (1.3%) ; Jim E. Smeeding, RPh, MBA The JeSTARx Group, Dallas, TX The TPG-National Payor Roundtable (TPG-NPRT) focuses on market access programs within the United States, is a subsidiary of The Pharmacy Group, and maintains a database of Chief Medical Officers and Chief Pharmacy Officers in the United States.
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